안과용 항VEGF 치료제 시장 기회, 성장요인, 업계 동향 분석 및 예측(2025-2034년)

The Global Ophthalmic Anti-VEGF Therapeutics Market was valued at USD 16.9 billion in 2024 and is estimated to grow at a CAGR of 5.2% to reach USD 28.6 billion by 2034.

Market expansion is driven by the rise in retinal disorders, the global increase in diabetes, continued population aging, and the rapid establishment of specialized ophthalmic facilities. Anti-VEGF drugs work by blocking VEGF activity, which contributes to abnormal blood vessel formation in the retina, making these therapies essential for conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Increasing cases of diabetic retinopathy, diabetes-related macular complications, and age-related visual degeneration continue to widen the treatment pool. At the same time, continual research efforts are delivering improved molecules with longer durability, enhanced safety, and multi-pathway targeting capabilities. These innovations are reshaping treatment patterns by expanding options for first-line therapies, optimizing switching strategies, and supporting longer dosing intervals. As the therapeutic landscape diversifies, premium drug categories remain commercially viable due to clinical performance and sustained demand across aging and diabetic populations.

The Eylea segment held a 57.2% share in 2024, supported by strong clinical outcomes, reliable safety, and longer dosing cycles enabled by its higher-dose formulation. Its broad adoption in diabetic retinal diseases is reinforced by the fast-growing global diabetic population, which consistently drives long-term utilization and high annual treatment volumes.

The age-related macular degeneration segment accounted for a 48.3% share in 2024 and is expected to reach USD 13.2 billion through 2034. As AMD primarily affects older adults, markets with rapidly expanding senior populations continue to see rising therapy demand. Anti-VEGF treatment remains the cornerstone of AMD care, resulting in steady growth across aging demographics worldwide.

North America Ophthalmic Anti-VEGF Therapeutics Market held a 64.8% share in 2024, supported by a large patient base with AMD, DME, and diabetic retinopathy. The region benefits from robust clinical infrastructure, extensive specialist availability, and highly efficient supply and administration systems that facilitate ongoing treatment adherence.

Major companies participating in the Global Ophthalmic Anti-VEGF Therapeutics Market include AMGEN, Astellas, Biocon Biologics, Biogen, CELLTRION, Intas Pharmaceuticals, KANGHONG PHARMACEUTICALS, LUPIN, NOVARTIS, REGENERON, Reliance Life Sciences, Roche, SANDOZ, STADA, and Teva. Companies operating in the Ophthalmic Anti-VEGF Therapeutics Market are adopting several strategic approaches to strengthen their position. Many are investing heavily in next-generation molecules with extended durability to reduce injection burden and improve patient outcomes. Firms are expanding clinical trials across multiple retinal conditions to broaden therapeutic indications and secure a larger market share. Partnerships, co-development agreements, and biosimilar expansion strategies are helping companies reach new geographies and diversify product portfolios. Manufacturers are also prioritizing real-world evidence programs to reinforce clinical value and support reimbursement negotiations.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Anti-VEGF therapies trends
  • 2.2.3 Drug type trends
  • 2.2.4 Indication trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of eye diseases
    • 3.2.1.2 Rise in aging population
    • 3.2.1.3 Technological advancements in drug development
    • 3.2.1.4 Growing awareness towards timely treatment of ophthalmic disorders
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Side effects and safety concerns
  • 3.2.3 Market opportunities
    • 3.2.3.1 Biosimilars and lower-cost alternatives expanding access
    • 3.2.3.2 Expansion into emerging markets with growing healthcare access
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends
• 3.7 Pipeline analysis
• 3.8 Pricing analysis, 2024
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
• 4.4 Competitive positioning matrix
• 4.5 Competitive analysis of major market players
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Anti-VEGF Therapies, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Eylea
• 5.3 Vabysmo
• 5.4 Lucentis
• 5.5 Other anti-VEGF therapies

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Biologics
• 6.3 Biosimilars

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Age-related macular degeneration
• 7.3 Diabetic retinopathy
• 7.4 Macular edema
• 7.5 Retinal vein occlusion
• 7.6 Myopic choroidal neovascularization

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AMGEN
• 9.2 Astellas
• 9.3 Biocon Biologics
• 9.4 Biogen
• 9.5 CELLTRION
• 9.6 Intas Pharmaceuticals
• 9.7 KANGHONG PHARMACEUTICALS
• 9.8 LUPIN
• 9.9 NOVARTIS
• 9.10 REGENERON
• 9.11 Reliance Life Sciences
• 9.12 Roche
• 9.13 SANDOZ
• 9.14 STADA
• 9.15 teva